Posters
View PosterSafety, Tolerability, and Biological Activity of AXA1125 and AXA1957 in a Prospective 16-Week Randomized, Placebo-Controlled Study in Subjects With NAFLD With and Without Type 2 Diabetes
Stephen A. Harrison, Nadege T. Gunn, Seth J. Baum, Ziad H. Younes, Anita Kohli, Rashmee Patil, Margaret J. Koziel, Harinder Chera, Jeff Zhao, and Manu V. Chakravarthy
Abstract 1694 | The Liver Meeting® 2020, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
Introduction Nonalcoholic fatty liver disease (NAFLD) is associated with a spectrum of histologic manifestations, including isolated steatosis, steatohepatitis, fibrosis, and cirrhosis. Patients with complex multifactorial diseases like NAFLD and nonalcoholic steatohepatitis (NASH) may benefit from approaches that concordantly address multiple metabolic and fibroinflammatory pathways. Endogenous metabolic modulators (EMMs) encompass a broad set of molecular families…